German researchers were stunned to discover that whole-body staging of patients with recently diagnosed malignancies using either MRI or PET/CT could miss a substantial number of metastatic lesions. They released their data at the 2007 RSNA meeting.
German researchers were stunned to discover that whole-body staging of patients with recently diagnosed malignancies using either MRI or PET/CT could miss a substantial number of metastatic lesions. They released their data at the 2007 RSNA meeting.
Dr. Florian Vogt and colleagues at the University Hospital of Essen enrolled 60 consecutive patients who underwent whole-body 1.5T MRI and whole-body FDG-PET/CT for staging of regional and distant melanoma metastases after primary tumor resection. Fifty-six patients completed the mean follow-up of 748 days. The researchers found that a significant number of patients initially staged as negative eventually proved to have undetected metastatic disease.
Another research group from Essen led by Dr. Gerald Antoch also evaluated the accuracy of whole-body FDG-PET/CT and whole-body MRI for staging and detection of bone metastases in 55 patients with melanoma and 54 with non-small cell lung cancer. The investigators found that, despite their accuracy for detection and staging, both tests yielded a significant rate of false negatives.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.